Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel Free ALKS Stock Alerts

Alkermes (ALKS) Competitors

Alkermes logo
$45.97 -0.14 (-0.30%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$46.00 +0.02 (+0.05%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ALKS vs. ABEO, MEDP, OMCL, AMN, and INSM

Should you buy Alkermes stock or one of its competitors? Alkermes's main competitors and comparable companies include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Alkermes compare to Abeona Therapeutics?

Alkermes (NASDAQ:ALKS) and Abeona Therapeutics (NASDAQ:ABEO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Alkermes has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alkermes has a net margin of 3.96% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Abeona Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes3.96% 4.15% 2.19%
Abeona Therapeutics N/A -41.69%-30.36%

Alkermes presently has a consensus target price of $54.56, suggesting a potential upside of 18.69%. Abeona Therapeutics has a consensus target price of $19.33, suggesting a potential upside of 257.36%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.72
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.67B4.62$241.66M$0.38120.97
Abeona Therapeutics$5.82M53.15$71.18M-$1.09N/A

In the previous week, Alkermes and Alkermes both had 6 articles in the media. Alkermes' average media sentiment score of 0.99 beat Abeona Therapeutics' score of 0.57 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abeona Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alkermes beats Abeona Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Alkermes compare to Medpace?

Medpace (NASDAQ:MEDP) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medpace$2.53B6.48$451.12M$17.0634.44
Alkermes$1.67B4.62$241.66M$0.38120.97

In the previous week, Medpace had 3 more articles in the media than Alkermes. MarketBeat recorded 9 mentions for Medpace and 6 mentions for Alkermes. Medpace's average media sentiment score of 1.47 beat Alkermes' score of 0.99 indicating that Medpace is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medpace
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Medpace presently has a consensus target price of $595.20, indicating a potential upside of 1.31%. Alkermes has a consensus target price of $54.56, indicating a potential upside of 18.69%. Given Alkermes' stronger consensus rating and higher possible upside, analysts clearly believe Alkermes is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace
0 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
Alkermes
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.72

Medpace has a net margin of 17.67% compared to Alkermes' net margin of 3.96%. Medpace's return on equity of 110.15% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Medpace17.67% 110.15% 24.84%
Alkermes 3.96%4.15%2.19%

78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Medpace beats Alkermes on 11 of the 17 factors compared between the two stocks.

How does Alkermes compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

In the previous week, Omnicell had 1 more articles in the media than Alkermes. MarketBeat recorded 7 mentions for Omnicell and 6 mentions for Alkermes. Omnicell's average media sentiment score of 1.51 beat Alkermes' score of 0.99 indicating that Omnicell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omnicell
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Alkermes
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has a net margin of 3.96% compared to Omnicell's net margin of 3.13%. Omnicell's return on equity of 5.66% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
Omnicell3.13% 5.66% 3.57%
Alkermes 3.96%4.15%2.19%

97.7% of Omnicell shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alkermes has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omnicell$1.25B1.20$2.05M$0.8439.04
Alkermes$1.67B4.62$241.66M$0.38120.97

Omnicell presently has a consensus target price of $57.86, indicating a potential upside of 76.45%. Alkermes has a consensus target price of $54.56, indicating a potential upside of 18.69%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78
Alkermes
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.72

Summary

Omnicell beats Alkermes on 9 of the 17 factors compared between the two stocks.

How does Alkermes compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Alkermes had 3 more articles in the media than AMN Healthcare Services. MarketBeat recorded 6 mentions for Alkermes and 3 mentions for AMN Healthcare Services. Alkermes' average media sentiment score of 0.99 beat AMN Healthcare Services' score of 0.92 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$3.43B0.38-$95.70M$2.6812.44
Alkermes$1.67B4.62$241.66M$0.38120.97

AMN Healthcare Services has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AMN Healthcare Services presently has a consensus target price of $36.00, indicating a potential upside of 8.02%. Alkermes has a consensus target price of $54.56, indicating a potential upside of 18.69%. Given Alkermes' stronger consensus rating and higher possible upside, analysts plainly believe Alkermes is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Alkermes
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.72

Alkermes has a net margin of 3.96% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Alkermes' return on equity.

Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services3.06% 19.92% 5.93%
Alkermes 3.96%4.15%2.19%

Summary

Alkermes beats AMN Healthcare Services on 11 of the 17 factors compared between the two stocks.

How does Alkermes compare to Insmed?

Insmed (NASDAQ:INSM) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Insmed currently has a consensus price target of $205.52, suggesting a potential upside of 58.81%. Alkermes has a consensus price target of $54.56, suggesting a potential upside of 18.69%. Given Insmed's stronger consensus rating and higher possible upside, research analysts clearly believe Insmed is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
0 Hold rating(s)
22 Buy rating(s)
2 Strong Buy rating(s)
3.00
Alkermes
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.72

95.2% of Alkermes shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Insmed has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

In the previous week, Insmed had 5 more articles in the media than Alkermes. MarketBeat recorded 11 mentions for Insmed and 6 mentions for Alkermes. Insmed's average media sentiment score of 1.15 beat Alkermes' score of 0.99 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
8 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$1.14B24.84-$1.28B-$4.11N/A
Alkermes$1.67B4.62$241.66M$0.38120.97

Alkermes has a net margin of 3.96% compared to Insmed's net margin of -76.94%. Alkermes' return on equity of 4.15% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-76.94% -123.94% -44.30%
Alkermes 3.96%4.15%2.19%

Summary

Alkermes beats Insmed on 9 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALKS vs. The Competition

Export
MetricAlkermesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.71B$3.84B$7.14B$12.72B
Dividend YieldN/A3.63%2.56%11.15%
P/E Ratio120.9814.25275.2425.29
Price / Sales4.621,473.16656.0298.94
Price / Cash27.54106.6877.0451.44
Price / Book4.1715.1210.336.20
Net Income$241.66M-$22.86M$3.50B$358.50M
7 Day Performance-0.28%-4.34%-3.32%-2.35%
1 Month Performance-8.57%-0.02%-0.41%-2.77%
1 Year Performance70.45%40.64%19.21%7.63%

Alkermes Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
2.8628 of 5 stars		$45.97
-0.3%		$54.56
+18.7%		+65.9%$7.71B$1.67B120.982,050
ABEO
Abeona Therapeutics
1.914 of 5 stars		$6.00
flat		$19.33
+222.2%		-19.9%$343.10M$5.82MN/A90
MEDP
Medpace
2.5911 of 5 stars		$591.29
flat		$595.20
+0.7%		+18.1%$16.50B$2.53B34.666,200
OMCL
Omnicell
4.4221 of 5 stars		$34.37
flat		$57.86
+68.3%		-1.5%$1.56B$1.18B40.923,580
AMN
AMN Healthcare Services
2.151 of 5 stars		$33.80
flat		$31.43
-7.0%		+76.1%$1.31B$2.73B12.612,664

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ALKS) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
I called NVDA at $6 - Here's what’s next…
Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...
Monument Traders Alliance | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel